Portage Biotech Reports FY24 Net Result Of $(75.4)M Vs $(104.7)M Last Year; Says Discontinuing INKT Clinical Trial For PORT-2; Continues To Explore Strategic Alternatives, Including Restructurings (Both In And Out Of Court)
Portage Biotech Reports FY24 Net Result Of $(75.4)M Vs $(104.7)M Last Year; Says Discontinuing INKT Clinical Trial For PORT-2; Continues To Explore Strategic Alternatives, Including Restructurings (Both In And Out Of Court)
The decrease was primarily due to lower non-cash losses on impairment related to the Company's identifiable intangible assets, goodwill, and certain investments and convertible note receivable.
主要是由於公司可識別無形資產、商譽、某些投資和可轉換票據應收款的非現金減值損失降低所致。
As of March 31, 2024, the Company had cash and cash equivalents of approximately $5.0 million and total current liabilities of approximately $2.9 million.
截至2024年3月31日，公司的現金及現金等價物約爲$500萬，總流動負債約爲$290萬。
"After reviewing Portage's funding requirements, which necessitated discontinuing the clinical development of its iNKT program and pausing patient enrollment in the ADPORT-601 clinical trial of PORT-6 (adenosine 2A inhibitor) and PORT-7 (adenosine 2B inhibitor), we continue to explore strategic alternatives. These may include finding a partner for one or more of our assets, a sale of our company, a merger, restructurings (both in and out of court), a company wind down, further financing efforts, or other strategic actions," said Dr. Ian Walters, Chief Executive Officer and Chairman of Portage.
波提奇醫療首席執行官兼主席伊恩·沃爾特斯博士表示：「在審查波提奇的資金需求後，我們不得不停止該公司iNKt項目的臨床開發和ADPORt-601臨床試驗的患者入組，並繼續探索戰略性選擇，其中可能包括尋找一些資產的合作伙伴、銷售我們的公司、合併、重組（在和外出庭時）、公司解散、進一步融資或其他戰略性措施。」